Tuesday, April 20, 2021
- Advertisement -
Home World European Commission: Procurement of German Sputnik is not a problem

European Commission: Procurement of German Sputnik is not a problem

To email the article, click here or copy and paste this link: https://magyarnemzet.hu/kulfold/europai-bizottsag-nem-gond-a-nemet-szputnyik-beszerzes-9630794/


EU member states can also obtain and use vaccines other than those included in the EU’s vaccination strategy to vaccinate their citizens, Eric Mamer, a spokesman for the European Commission, told a press conference in Brussels on Thursday. Asked that Germany had announced on Thursday that it would start talks with Russia on the acquisition of a Russian vaccine against the coronavirus Sputnik V on a bilateral basis, independently of the European Union, Eric Mamer replied:

Member States have the possibility to negotiate and conclude procurement agreements with pharmaceutical companies whose vaccine is not included in the EU vaccination program.

“This is not the end of the EU’s vaccination strategy,” he said. He added, however, that Member States could not derogate from the conditions laid down in jointly agreed agreements regarding the procurement of vaccines under the EU vaccination program. The European Commission has so far identified Johnson & Johnson (400 million doses), BioNTech-Pfizer (600 million doses), Moderna (460 million doses), AstraZeneca (400 million doses), CureVac (405 million doses) and Sanofi. –Signed a vaccine contract with GSK (300 million doses).

Stefan De Keersmaecker, the relevant spokesperson for the European Commission, emphasized at the press conference:

the most important thing for the panel is to bring safe vaccines to the EU market.

- Advertisement -

However, vaccination and the vaccination campaign are a matter for the Member States, he added. The European Medicines Agency (EMA) is making important findings on the safety and effectiveness of vaccines, but as vaccination policy is a Member State competence, Member States may choose to follow a stricter approach to vaccines than the EMA recommendations, he warned.

Concerning that a link between the very rare cases of blood clotting disorders previously reported and AstraZeneca’s vaccine was reported to be possible, the spokesman said the EU contract with the British-Swedish pharmaceutical company was still valid. He also said that the EU would monitor the epidemiological situation and continue to investigate potential vaccines and medicines already on the market and against the coronavirus with experts from the EMA and the European Center for Disease Prevention and Control.



RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisment -

Most Popular

Recent Comments